Designing a new generation of bacteria for cancer therapy
GenCirq's novel bacterial platform enables production and delivery of therapeutics at disease sites within the human body.
Our technology leverages the latest advances in synthetic biology to engineer bacteria for the treatment of disease.
Why we engineer bacteria for cancer therapy:
Disease target
Bacteria selectively colonize the necrotic cores of solid tumors following systemic delivery.
Safety
Probiotic strains of bacteria are widely consumed, and further engineering enhances safety.
Engineering
Bacteria are engineered with synthetic biology control systems and genetically encode a wide range of therapeutics.
Cost
Bacteria are quickly propagated under simple growth conditions.
Our Strategy
We program probiotic or clinically-relevant bacteria that naturally possess tumor-homing capabilities to deliver therapeutics to tumors.
Our Synchronized Lysis Circuit results in local delivery of therapeutics and enhances the safety and efficacy of cancer therapies.